

PCT

BEST AVAILABLE COPY

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁶ : A01K 67/027</p>	<p>A1</p>	<p>(11) International Publication Number: WO 99/16307 (43) International Publication Date: 8 April 1999 (08.04.99)</p>
<p>(21) International Application Number: PCT/US98/19614 (22) International Filing Date: 18 September 1998 (18.09.98) (30) Priority Data: 08/938,987 26 September 1997 (26.09.97) US (71) Applicant: CEDARS-SINAI MEDICAL CENTER [US/US]; 8700 Beverly Boulevard, Los Angeles, CA 90048 (US). (72) Inventor: VIERLING, John, M.; 407 South Spaulding Drive #5, Beverly Hills, CA 90212 (US). (74) Agents: CRAFT, Jeffrey, F. et al.; Pretty, Schroeder & Poplawski, 19th floor, 444 South Flower Street, Los An- geles, CA 90071 (US).</p>		<p>(81) Designated States: AU, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: <i>IN VIVO</i>, ANIMAL MODEL FOR EXPRESSION OF HEPATITIS C VIRUS</p> <p>(57) Abstract</p> <p>Disclosed is a method for expressing hepatitis C virus in an <i>in vivo</i>, animal model. Viable, hepatitis C virus-infected, human hepatocytes are transplanted into a liver parenchyma of a scid/scid mouse host. The scid/scid mouse host is then maintained in a viable state, for up to five days or greater, whereby viable, morphologically intact human hepatocytes persist in the donor tissue and hepatitis C virus is replicated in the persisting human hepatocytes.</p> <div data-bbox="776 1102 1372 1423"></div> <div data-bbox="776 1549 1372 1879"></div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

IN VIVO, ANIMAL MODEL FOR EXPRESSION OF HEPATITIS C VIRUS

BACKGROUND OF THE INVENTION

Field of the Invention.

This invention relates to the medical arts. In particular, it relates to a model for studying
5 hepatitis C virus and for a method for preparing the model.

Discussion of the Related Art.

The use of heterologous transplants in a host has found wide application in research and therapy. The ability to transplant tissue from one host to another allows for opportunities of scientific investigation which are not available in the source host. For example, it has proved
10 possible to create chimeras from severe combined immunodeficiency ("scid/scid" or "SCID") mice host and human donors for studies of the organ-specificity of metastatic malignance and functions of human leukocytes. However, no validated animal models for the expression of hepatitis C virus ("HCV") have been reported.

There has also been reported the grafting of xenogeneic tissue beneath the renal capsule
15 of immunocompromised mouse hosts. However, the renal capsule as a site for introduction of xenogeneic tissue has many drawbacks. It is physically difficult to introduce the tissue, so that there is a significant number of failures in producing functional organs. Also, vascularization is not as extensive as one would wish. In addition, the tissue did not maintain a desirable growth pattern. There remains, therefore, interest in being able to develop alternative sites and methods
20 for introduction of xenogeneic tissue into anatomical sites of target hosts.

In particular, there remains a definite need for an *in vivo* animal model for studying HCV. There remains a further definite need for a method for transplanting leukocyte depleted or relatively large HCV-infected liver tissue samples into the homologous organ. There remains a still further definite need for a method for transplanting xenogeneic HCV-infected hepatocytes
25 that remain viable and morphologically intact in the donor tissue and replicate HCV. The present invention satisfies these and other needs and provides further related advantages.

SUMMARY OF THE INVENTION

The present invention, which addresses the above needs, is embodied in a method for expressing hepatitis C virus in an *in vivo*, animal model. Viable, hepatitis C virus-infected, human hepatocytes are transplanted into a liver parenchyma of a scid/scid mouse host. The
5 scid/scid mouse host is then maintained in a viable state, for up to five days or greater, whereby viable, morphologically intact human hepatocytes persist in the donor tissue and hepatitis C virus is replicated in the persisting human hepatocytes.

In some embodiments, the scid/scid mouse host is an H-2^d scid/scid mouse host. Further, in some embodiments the hepatocytes to be transplanted are obtained from a percutaneous liver
10 biopsy and, in some embodiments, the hepatocytes are depleted of leukocytes prior to transplanting. The resulting human hepatic-SCID chimera provides an environment suitable for the persistence and function of the transplanted tissue and maintenance of the architectural arrangement of the human hepatocytes.

BRIEF DESCRIPTION OF THE FIGURES

15 FIGS. 1A and 1B show a percutaneous liver biopsy specimen from a patient with chronic hepatitis, under low and high power magnification, respectively.

FIGS. 2A-2C show a hepatitis C virus-infected, human liver tissue xenograft five days after transplantation in accordance with the invention, under three powers of magnification.

FIGS. 3A-3C show results of molecular virologic tests demonstrating the presence of
20 hepatitis C viremia in the blood of the human hepatic-SCID chimera prepared in accordance with the invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

Methods and chimeric immunocompromised heterologous mammalian hosts, particularly mouse hosts, are provided for the expression of hepatitis C virus ("HCV"). The chimeric hosts
25 have transplanted in their liver parenchyma viable, hepatitis C virus-infected human liver tissue having morphologically intact hepatocytes. transplanted into a viable, hepatitis C virus-infected human hepatocytes in the liver of an immunocompromised host.

The mammals are immunocompromised in normally inheriting the desired immune incapacity or the desired immune incapacity may be created. For example, host with severe
30 combined immunodeficiency, known as scid/scid hosts, are available. Rodentia, particularly

mice, and equine, particularly horses, are presently available as scid/scid hosts (hereinafter referred to as scid/scid hosts). The scid/scid hosts lack functioning lymphocyte types, particularly B-cells and some T-cell types. In the scid/scid mouse hosts, the genetic defect appears to be a non-functioning recombinase, for the germline DNA is not rearranged to produce functioning surface immunoglobulin and T-cell receptors.

The xenograft will occur with a host at an age less than about 25% of its normal lifespan, usually to 20% of the normal lifespan with mice, and the age will generally be an age of about 3 to 10 weeks, more usually from about 4 to 8 weeks. The mice may be of either sex, may be neutered, and may be otherwise normal, except for the immunocompromised state, or may have one or more mutations, which may be naturally occurring or as a result of mutagenesis.

The viable, human hepatocytes to be xenografted are obtained from human donors infected with HCV. It is an advantage of the invention that different HCV genotypes and HLA haplotypes can be studied by choosing tissue from different donors. The tissue may be fresh tissue, suitably obtained using a percutaneous liver biopsy, or freshly frozen tissue, tissue frozen within about 12 hours of such a biopsy and then maintained at below -10°C., usually at about liquid nitrogen temperature (-70°C) indefinitely.

The hepatocytes may be provided as individual cells freed of attached stromal elements or as small tissue slices. To facilitate xenografting of HCV-infected hepatocytes for studies of human hepatic/viral gene expression in the absence of inflammation and to study the consequences of subsequent adoptive transfer of autologous effector cells, in some embodiments, it is desirable to first deplete the liver biopsy specimens of inflammatory cells. The specimens are rocked in a medium supplemented with DNAase I, collagenase D and hyaluronidase to disrupt the cell adhesion and gently pipetted to produce a single cell suspension containing hepatic parenchyma cells, biliary epithelial cells and mononuclear inflammatory cells. The cell suspension is then incubated with mAb specific for CD45 (mouse IgG1, κ ; PharMingen), that reacts with an antigen ubiquitously present on the surface membranes of human leukocytes. CD45+ is absent from non-hemopoietic cells, including all epithelial cells. Depletion of CD45+ cells is performed using immunomagnetic beads coated with anti-mouse Ig. The remaining hepatic cells are centrifuged into a pellet and mixed with a fresh drop of autologous blood (tail vein) to create a transplantable graft.

In other embodiments small tissue slices are transplanted. The small tissue slices are usually of length from about 0.5 mm to 4 mm, more usually from about 1 mm to 2 mm, and

usually of a thickness in the range of about 1 to 2 mm, so that the sections can easily fit into a trocar used for implantation, usually conveniently of about 15- to 20 gauge. It is an advantage of the invention that such relatively large specimens can be used, because their large size facilitates both transplanting and the subsequent vascularization.

5 Methods of inserting the hepatocytes into the liver parenchyma of the mouse host are within the skill of the ordinary artisan. In a representative method, six to eight week-old, female, H-2^d scid/scid mice are used as the hosts. Xenografting is performed through a 2 cm laparotomy incision created under methoxyfluorane general anesthesia. The hepatocytes are transplanted into the parenchyma of the right hepatic lobe. Homeostasis is achieved with
10 gelfoam, and the wound is closed with absorbable subcuticular sutures.

EXAMPLE

Liver biopsy

A percutaneous liver biopsy performed in a thirty-seven year-old adult woman was placed in Wisconsin preservation solution on ice and transported to a laboratory. At the
15 laboratory, the biopsy specimen was extensively washed with Hank's balanced salt solution at room temperature to remove the preservation solution and the blood within the liver tissue's sinusoids.

Xenografting of Human Liver

The HCV-infected liver tissue was then transplanted into the liver of a six week-old
20 female H-2^d SCID mouse (obtained from Jackson Laboratory, Bar Harbor, Maine) anesthetized using inhaled methoxflurane in a Bell jar. Anesthesia was maintained during surgery using a nose cone. The abdominal hair was clipped and the abdomen skin was sterilized. A sterile plastic drape was placed over the abdomen, and a midline laparotomy was performed to expose the liver. Using a scalpel, a 3 mm incision was made parallel to the vascular planes of an
25 hepatic lobe, and the wound was immediately packed with a gelfoam pledget soaked in sterile normal saline to create a pouch. Homeostasis was rapidly achieved and total blood loss was insignificant. After achieving homeostasis, the gelfoam pledget was removed, and the human liver biopsy segment was inserted into the pouch. The surface of the mouse liver spontaneously closed over the xenograft. The peritoneum and skin were closed with absorbable suture
30 materials. The mouse regained consciousness in a few minutes and moved about normally.

Histopathology of the Hepatic Xenograft

Five full days after xenotransplantation, the mouse was euthanized using cervical dislocation under ketamine anesthesia. The liver containing the xenograft was excised and fixed in 10% buffered formalin for histopathological examination. Histologic sections were stained with hematoxylin and eosin.

Molecular Virologic Studies

Blood obtained at the time of euthanasia was centrifuged to prepare serum. RNA was extracted from both the mouse serum and the serum of a patient with documented hepatitis C viremia. HCV RNA PCR assays were performed using the one-step method described in Hu K-Q, Yu C-H and Vierling, "One Step RNA PCR for Detection of HCV RNA," *Hepatology*, 1993; 18: 270-74, which reference is herein incorporated by reference. The HCV specificity of the cDNA products was confirmed using Southern blot hybridization with a ³²P-labeled probe specific for HCV cDNA.

Histopathology of Liver Biopsy Specimen

FIGS. 1A and 1B show a percutaneous liver biopsy specimen from a patient with chronic hepatitis under low and high power magnification, respectively. At both low and high power magnification, micro- and macrovesicular fat can be seen in some hepatocytes.

Histopathology of Hepatic Xenograft

As seen in FIG. 2A, the human hepatic xenograft was readily distinguished from the adjacent mouse liver based on differences in hematoxylin and eosin staining characteristics. The normal architecture of the human parenchyma was preserved with hepatocytes arranged in cords within sinusoids (FIG. 2B). The human hepatocytes continued to express both micro- and macrovesicular fat observed in the original biopsy (FIG. 2C).

HCV RNA PCR of Mouse Host Blood

The HCV RNA PCR results using mouse blood are shown in FIG. 3. Using the one-step HCV RNA PCR method (FIG. 3A), the appropriate size of cDNA product was observed using RNA isolated from the blood of the host mouse and the serum of a patient with documented HCV viremia. No reaction product was observed in the negative control (RNA isolated from

the blood of a native scid/scid mouse). Using a "nested" HCV RNA PCR technique (FIG. 3B), the appropriate size of cDNA products were also observed for the host mouse and a positive control. No reaction product was observed in the negative control. Southern blot hybridization (FIG.3C) confirmed the HCV-specificity of the cDNA products.

- 5 The inventive *in vivo* model permits study of HCV and host gene expression, in the presence and absence of host leukocytes, using infected liver tissue from human donors with different HCV genotypes and different HLA haplotypes. After maintaining the mouse for up to about five days or longer, the liver tissue is at least partially vascularized and generally highly vascularized. The liver tissue is not rejected, because of the severe immunodeficiency
- 10 of the SCID mouse. Further, because the infected liver tissue is transplanted into a homologous organ, there is provided an environment suitable for the persistence and function of the grafted tissue and maintenance of the architectural arrangement of the human hepatocytes. The liver tissue grows rapidly, and assumes an architecture substantially similar associated with the donor liver tissue. The type, quantity, and spatial organization of the cells is similar to that
- 15 found in the donor liver. And because the HCV is replicated in the persisting human hepatocytes, the mouse becomes viremic.

CLAIMS

1. A method for expressing hepatitis C virus in an *in vivo*, animal model comprising the steps of:

transplanting viable, hepatitis C virus-infected, human hepatocytes into a liver parenchyma of a scid/scid mouse host; and

maintaining the scid/scid mouse host in a viable state, whereby viable, morphologically intact human hepatocytes persist and hepatitis C virus is replicated in the persisting human hepatocytes.

2. The method in accordance with claim 1 wherein the scid/scid mouse host is an H-2^d scid/scid mouse host.

3. The method in accordance with claim 2 further comprising obtaining the hepatocytes to be transplanted by a percutaneous liver biopsy.

4. The method in accordance with claim 3 further comprising depleting the hepatocytes of leukocytes prior to transplanting.

5. The method in accordance with claim 3 wherein the mouse host is maintained in the viable state for at least about five days.

6. A method for preparing an *in vivo*, animal model for expressing hepatitis C virus comprising the steps of:

transplanting a viable, hepatitis C virus-infected liver tissue from a human donor into a liver parenchyma of a scid/scid mouse host; and

maintaining the mouse host, whereby the human liver tissue becomes at least partially vascularized.

7. The method in accordance with claim 6 wherein the scid/scid mouse host is an H-2^d scid/scid mouse host.

8. The method in accordance with claim 7 further comprising obtaining the liver tissue to be transplanted by a percutaneous liver biopsy.

9. The method in accordance with claim 8 further comprising depleting the liver tissue of leukocytes prior to transplanting.

10. The method in accordance with claim 8 wherein the mouse host is maintained in the viable state for at least about five days.

11. A scid/scid mouse host comprising:
a viable, hepatitis C virus-infected human liver tissue having morphologically intact hepatocytes transplanted into a liver parenchyma of a scid/scid mouse host.

FIG. 1A



FIG. 1B

FIG. 2A




FIG. 2B




FIG. 2C

FIG. 3A




FIG. 3B




FIG. 3C

INTERNATIONAL SEARCH REPORT

Inter. Appl. No.
PCT/US 98/19614

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 A01K67/027		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 A01K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GALUN, E. ET AL.: "Hepatitis C virus viremia in SCID-BNX mouse chimera" JOURNAL OF INFECTIOUS DISEASES, vol. 172, no. 1, July 1995, pages 25-30, XP002090531 see page 27, column 2, paragraph 3 ---	1
A	WO 94 27556 A (YEDA RES & DEV ;DAGAN SHLOMO (US)) 8 December 1994 see claims; figure 4; examples 4,5 ---	1
A	WO 94 02601 A (UNIV PENNSYLVANIA ;UNIV WASHINGTON (US); CHILDRENS HOSP MEDICAL CE) 3 February 1994 see page 11, line 24 - page 12, line 11; claims 1-9,20,37,38 see page 13, paragraph 3 see page 14, paragraph 3 ---	1
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents: <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center;">21 January 1999</div>	Date of mailing of the international search report <div style="text-align: center;">01/02/1999</div>	
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer <div style="text-align: center;">Chambonnet, F</div>	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/19614

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 96 39810 A (SANDOZ LTD ;SYSTEMIX INC (US); SANDOZ AG (AT); SANDOZ AG (DE)) 19 December 1996 see page 5, paragraph 2 -----</p>	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/19614

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9427556 A	08-12-1994	US 5652373 A	29-07-1997
		AU 6949994 A	20-12-1994
		CA 2161798 A	08-12-1994
		EP 0699235 A	06-03-1996
		JP 8511937 T	17-12-1996
		US 5849987 A	15-12-1998
		US 5804160 A	08-09-1998
		US 5709843 A	20-01-1998
WO 9402601 A	03-02-1994	US 5849288 A	15-12-1998
		AU 676194 B	06-03-1997
		AU 4778293 A	14-02-1994
		CA 2140785 A	03-02-1994
		EP 0652949 A	17-05-1995
WO 9639810 A	19-12-1996	JP 7509363 T	19-10-1995
		AU 6222996 A	30-12-1996

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.